Erytech Pharma
Records under this name other than the patents Erytech Pharma holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 13 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,286,008 | Method for Stabilising Suspensions of Red Blood Cells Encapsulating an Active Ingredient, the Suspensions Obtained Formerly held In force · High confidence | In force | High confidence | |
| US 11,273,210 | Arginine Deiminase Encapsulated Inside Erythrocytes and Their Use in Treating Cancer and ARGINASE-1 Deficiency Formerly held In force (reinstated) · High confidence | In force (reinstated) | High confidence | |
| US 8,852,880 | Test for Predicting Neutralization of Asparaginase Activity Lapsed on the fee record Ended Oct 7, 2026 · High confidence | Lapsed on the fee record | Ended Oct 7, 2026 | High confidence |
| US 11,458,170 | Pharmaceutical Composition Comprising Erythrocytes Encapsulating a Plp-Dependent Enzyme and, a Non-Phosphate PLP Precursor Lapsed on the fee record Ended Oct 4, 2026 · High confidence | Lapsed on the fee record | Ended Oct 4, 2026 | High confidence |
| US 10,046,009 | Method of Treatment Using a Pharmaceutical Composition Comprising Erythrocytes Encapsulating a Plp-Dependent Enzyme and Its Cofactor Lapsed on the fee record Ended Aug 14, 2026 · High confidence | Lapsed on the fee record | Ended Aug 14, 2026 | High confidence |
| US 9,968,663 | Erythrocytes containing arginine deiminase Formerly held Term ended Term ended Apr 25, 2026 · From the USPTO record | Term ended | Term ended Apr 25, 2026 | From the USPTO record |
| US 9,950,049 | Composition and therapeutic anti-tumour vaccine Lapsed on the fee record Ended Apr 24, 2026 · From the USPTO record | Lapsed on the fee record | Ended Apr 24, 2026 | From the USPTO record |
| US 8,617,840 | Lysis/resealing process and device for incorporating an active ingredient, in particular asparaginase or inositol hexaphosphate, in erythrocytes Lapsed on the fee record Ended Dec 31, 2025 · From the USPTO record | Lapsed on the fee record | Ended Dec 31, 2025 | From the USPTO record |
| US 11,141,468 | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion Lapsed on the fee record Ended Oct 12, 2025 · From the USPTO record | Lapsed on the fee record | Ended Oct 12, 2025 | From the USPTO record |
| US 10,273,444 | Lysis/resealing process and device for incorporating an active ingredient, in particular asparaginase or inositol hexaphosphate, in erythrocytes Term ended Term ended Aug 4, 2025 · From the USPTO record | Term ended | Term ended Aug 4, 2025 | From the USPTO record |